Showing results (1-10 of 162) with videos related to
Sort By:
Pageof 17
Current Opinion in Immunology|July 29, 2025
Can we cure vasculitis?Meghan E Free, Dominic J Ciavatta, Ronald J FalkSeminars in Immunopathology|March 7, 2022
Mechanisms of vascular damage in ANCA vasculitisDavid Massicotte-Azarniouch, Carolina A Herrera, J Charles Jennette, et al.Rheumatology (Oxford, England)|March 12, 2025
The evolving landscape of vasculitis management: past, current and emergingRonald J Falk, Meghan E Free, Dominic J Ciavatta, et al.Rheumatology (Oxford, England)|March 12, 2025
Emerging cell therapies in the vasculitis fieldMeghan E FreeKidney International Reports|April 18, 2019
Understanding Long-term Remission Off Therapy in Antineutrophil Cytoplasmic Antibody-Associated VasculitisSusan L Hogan, Patrick H Nachman, Caroline J Poulton, et al.Journal of Autoimmunity|June 8, 2024
Regulatory T cells effectively downregulate the autoimmune anti-MPO response and ameliorate anti-MPO induced glomerulonephritis in micePeiqi Hu, Hong Xiao, Sandra Elmore, et al.Journal of the American Society of Nephrology : JASN|July 26, 2014
Dysregulation of autoantigen genes in ANCA-associated vasculitis involves alternative transcripts and new protein synthesisElizabeth A McInnis, Anshul K Badhwar, Akhil Muthigi, et al.Arthritis and Rheumatism|April 5, 2013
Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell populationMeghan E Free, Donna O'Dell Bunch, Julie Anne McGregor, et al.Clinical & Translational Immunology|November 16, 2022
The frequency of Treg subsets distinguishes disease activity in ANCA vasculitisChristian Agosto-Burgos, Eveline Y Wu, Marie A Iannone, et al.The Journal of Clinical Investigation|February 28, 2025
Sequential carbonyl derivatives and hydrazone adduct formation on myeloperoxidase contribute to development of ANCA vasculitisGang Xi, Elizabeth A Mclnnis, Olivier Lardinois, et al.Pageof 17